Clinical Efficacy of Combination Therapy of Ranibizumab and Different Doses of Vitipofen Photody-namic Therapy in the Treatment of CSC Complicated with CNV
[Objective]To explore the clinical efficacy of ranibizumab combined with different doses of vitipofen photo-dynamic therapy in the treatment of chronic central serous chorioretinopathy(CSC)with choroidal neovascularization(CNV).[Methods]A total of 103 patients with chronic CSC complicated with CNV admitted to Jiading District Central Hospital affiliated with Shanghai Health Medical College from February 2014 to December 2019 were selected.According to different treatment methods,they were divided into a conventional group[58 cases,58 eyes,treated with ranibizumab and low-dose(1 mg/m2)Vitipofen photodynamic therapy]and an observation group[55 cases,55 eyes,treated with ranibi-zumab and half dose(3 mg/m2)Vitipofen photodynamic therapy].We compared the clinical efficacy,incidence of adverse reactions,height of subretinal fluid protrusion(HPSF),best corrected visual acuity(BCVA),and hemodynamic parame-ters of the central retinal vein(Vmax and Vmin)between two groups of patients before and after treatment.[Results]The to-tal effective rate of the observation group was higher than that of the control group(P<0.05).Before treatment,there was no statistically significant difference in HPSF and BVCA between the two groups of patients(P>0.05);After treat-ment,HPSF was decreased in both groups,and the observation group was lower than the conventional group(P<0.05).After treatment,BCVA increased in both groups,and the observation group was higher than the conventional group(P<0.05).Before treatment,there was no statistically significant difference in Vmax and Vmin between the two groups of patients(P>0.05);After treatment,Vmax and Vmin decreased in both groups of patients,and the observation group was lower than the control group(P<0.05).In the conventional group,there was 1 case of elevated intraocular pressure,2 cases of nausea and vomiting,and the incidence of adverse reactions was 5.17%;In the observation group,there were 2 cases of el-evated intraocular pressure,2 cases of nausea and vomiting,and the incidence of adverse reactions was 7.27%.There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).[Conclusion]The combination of ranibizumab and half dose vitipofen photodynamic therapy had a significant effect on the treatment of chronic CSC complicated with CNV.It can improve the visual acuity and central retinal vein hemodynamic indicators of pa-tients,and is safe and reliable.
万方数据
维普
